• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: W.L. GORE & ASSOCIATES GORE® VIABAHN® ENDOPROSTHESIS; NIP

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

W.L. GORE & ASSOCIATES GORE® VIABAHN® ENDOPROSTHESIS; NIP Back to Search Results
Catalog Number JHJR081502J
Device Problems Inadequacy of Device Shape and/or Size (1583); Human-Device Interface Problem (2949); Appropriate Term/Code Not Available (3191)
Patient Problem Pain (1994)
Event Date 03/05/2018
Event Type  Injury  
Manufacturer Narrative
(b)(4).According to the gore® viabahn® endoprosthesis with heparin bioactive surface instructions for use (ifu), complications and adverse events can occur when using any endovascular device.These complications include, but are not limited to thrombosis or occlusion and migration.Migration of the endoprosthesis may require surgical intervention.Additionally, the ifu states: special care should be taken to ensure that the appropriate size endoprostheses are selected prior to introduction.Native vessel dimensions must be accurately measured, not estimated.
 
Event Description
On (b)(6) 2018, this patient underwent an endovascular repair for a left popliteal artery aneurysm using gore® viabahn® endoprosthesis with heparin bioactive surface.After two endoprostheses (8 mm x 15 cm, 8 mm x 10 cm) were deployed, it was reported that a slight distal type i endoleak remained.Reportedly, the endoleak occurred as the length of the endoprostheses was insufficient.The physician elected to monitor it and concluded the procedure.The patient reportedly tolerated the procedure.On (b)(6) 2018, the patient experienced pain of the left leg.On (b)(6) 2018, imaging showed that the endoprostheses and below-knee region were occluded.Migration of the distal placed endoprosthesis (jhjr081502j/unk ) was also observed.Reportedly, the endoprosthesis had migrated proximally around 2-3 cm.The endoleak was not visible on that date.On the same day, re-intervention was performed.Emergent thrombectomy was done from the left superficial femoral artery to the endoprostheses, and below-knee region.A gore® viabahn® endoprosthesis with heparin bioactive surface (8 mm x 25 cm) was additionally implanted in the left popliteal artery.Plain old balloon angioplasty was performed for the below-knee region.After that, the procedure was concluded.The patient reportedly tolerated the re-intervention.The physician reported that the endoprostheses were undersize against the patient artery, and the migration may be caused by knee bending and stretching.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
GORE® VIABAHN® ENDOPROSTHESIS
Type of Device
NIP
Manufacturer (Section D)
W.L. GORE & ASSOCIATES
flagstaff AZ
Manufacturer (Section G)
MEDICAL ECHO RIDGE B/P
3250 w. kiltie lane
flagstaff AZ 86005
Manufacturer Contact
nataliya baramzina
1500 n. 4th street
flagstaff, AZ 
9285263030
MDR Report Key7393464
MDR Text Key104213063
Report Number2017233-2018-00202
Device Sequence Number1
Product Code PFV
Combination Product (y/n)N
Reporter Country CodeJA
PMA/PMN Number
P040037
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative
Reporter Occupation Physician
Type of Report Initial
Report Date 03/19/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received04/03/2018
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Catalogue NumberJHJR081502J
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Hospitalization; Required Intervention;
Patient Age76 YR
-
-